Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis

Published:September 18, 2021DOI:https://doi.org/10.1016/j.jccase.2021.09.001

      Abstract

      Because cardiac involvement of amyloid A (AA) is not frequent, little is known about the effects of tocilizumab (TCZ; a humanized monoclonal anti-interleukin-6 receptor antibody). We present the case of a 77-year-old man with cardiac AA amyloidosis due to rheumatoid arthritis (RA). He was admitted to our hospital because of gastrointestinal bleeding. Upon admission, chest radiography and electrocardiogram showed progression of cardiomegaly and atrioventricular conduction delay, respectively. Echocardiography showed diffuse left ventricular (LV) hypertrophy with reduced LV contraction. AA amyloid deposits in the myocardium were identified by Congo red staining and immunohistochemical staining with anti-AA antibody, suggesting cardiac AA amyloidosis. After starting treatment with TCZ, his condition improved. Hypertrophic LV mass was significantly reduced, and impaired LV contraction was restored after 10 months of TCZ treatment. The effects of TCZ were sustained for 2 years. Plasma N terminal pro-B-type natriuretic peptide level decreased from 2947 pg/mL (reference level, <125 pg/mL) on admission to 325 pg/mL after 2 years of TCZ treatment. The present case supports that cardiac biopsy is very important to diagnose cardiac AA amyloidosis in patients with RA complicating unexplained cardiac hypertrophy and/or dysfunction and TCZ should be administered if applicable.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Dember LM
        • Hawkins PN
        • Hazenberg BP
        • Gorevic PD
        • Merlini G
        • Butrimiene I
        • Livneh A
        • Lesnyak O
        • Puéchal X
        • Lachmann HJ
        • Obici L.
        Eprodisate for the treatment of renal disease in AA amyloidosis.
        N Engl J Med. 2007; 356: 2349-2360
        • Lachmann HJ
        • Goodman HJ
        • Gilbertson JA
        • Gallimore JR
        • Sabin CA
        • Gillmore JD
        • Hawkins PN.
        Natural history and outcome in systemic AA amyloidosis.
        N Engl J Med. 2007; 356: 2361-2371
        • Okuda Y
        • Yamada T
        • Ueda M
        • Ando Y.
        First nationwide survey of 199 patients with amyloid A amyloidosis in Japan.
        Intern Med. 2018; 57: 3351-3355
        • Gómez-Casanovas E
        • Sanmartí R
        • Solé M
        • Cañete JD
        • Muñoz-Gómez J.
        The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration.
        Arthritis Rheum. 2001; 44: 66-72
        • Wakhlu A
        • Krisnani N
        • Hissaria P
        • Aggarwal A
        • Misra R.
        Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis.
        J Rheumatol. 2003; 30: 948-951
        • Okuda Y.
        AA amyloidosis - Benefits and prospects of IL-6 inhibitors.
        Mod Rheumatol. 2019; 29: 268-274
        • Okuda Y
        • Ohnishi M
        • Matoba K
        • Jouyama K
        • Yamada A
        • Sawada N
        • Mokuda S
        • Murata Y
        • Takasugi K.
        Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.
        Mod Rheumatol. 2014; 24: 137-143
        • Ohsugi Y.
        Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
        Biol Pharm Bull. 2007; 30: 2001-2006
        • Courties A
        • Grateau G
        • Philippe P
        • Flipo RM
        • Astudillo L
        • Aubry-Rozier B
        • Fabreguet I
        • Fahd W
        • Fain O
        • Guggenbuhl P
        • Hachulla E
        AA amyloidosis treated with tocilizumab: case series and updated literature review.
        Amyloid. 2015; 22: 84-92
        • Papathanasiou M
        • Carpinteiro A
        • Hagenacker T
        • Herrmann K
        • Rassaf T
        • Rischpler C
        • Luedike P.
        18 F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis.
        Eur J Nucl Med Mol Imaging. 2020; 47: 3186-3187